What Did the Phase 2 Retatrutide Trial Report?
Short answer: The phase 2 trial in adults with obesity, published by Jastreboff and colleagues in the New England Journal of Medicine in 2023, ran for 48 weeks and reported a mean body-weight reduction of 24.2% in the highest Retatrutide group against about 2% with placebo, with gastrointestinal effects the most common adverse events. It is the largest published human dataset for the compound.
The trial compared several Retatrutide groups with a placebo group and reported weight change as its primary outcome at 24 and 48 weeks. The reductions were larger than those reported for the single and dual receptor agonists in their own trials, which is why the compound attracted attention.
The paper reports what the groups experienced; it is not a protocol, and this page cites it as published science only. The pack is supplied for laboratory research and no guidance is given on its use.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Retatrutide Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.